#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Aging-associated disabilities are generated by an accumulation of randomly occurring molecular damages during life time , which affect the organism at multiple levels such as metabolism , immune response , repair , and regeneration as well as altered inter- and intracellular communication .
2-1	16-32	Aging-associated	abstract[2]	new[2]	_	_
2-2	33-45	disabilities	abstract[2]	new[2]	_	_
2-3	46-49	are	_	_	_	_
2-4	50-59	generated	_	_	_	_
2-5	60-62	by	_	_	_	_
2-6	63-65	an	abstract[3]	new[3]	coref	4-6[27_3]
2-7	66-78	accumulation	abstract[3]	new[3]	_	_
2-8	79-81	of	_	_	_	_
2-9	82-90	randomly	_	_	_	_
2-10	91-100	occurring	_	_	_	_
2-11	101-110	molecular	abstract[4]	new[4]	_	_
2-12	111-118	damages	abstract[4]	new[4]	_	_
2-13	119-125	during	_	_	_	_
2-14	126-130	life	abstract|abstract[6]	new|new[6]	_	_
2-15	131-135	time	abstract[6]	new[6]	_	_
2-16	136-137	,	_	_	_	_
2-17	138-143	which	_	_	_	_
2-18	144-150	affect	_	_	_	_
2-19	151-154	the	abstract[7]	new[7]	_	_
2-20	155-163	organism	abstract[7]	new[7]	_	_
2-21	164-166	at	abstract[7]	new[7]	_	_
2-22	167-175	multiple	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-23	176-182	levels	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-24	183-187	such	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-25	188-190	as	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-26	191-201	metabolism	abstract[7]|abstract[8]|abstract	new[7]|new[8]|new	coref	22-22[182_0]
2-27	202-203	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-28	204-210	immune	abstract[7]|abstract[8]|abstract|abstract[11]	new[7]|new[8]|new|new[11]	coref|coref|coref|coref	12-8[82_11]|15-17|12-8[82_11]|15-17
2-29	211-219	response	abstract[7]|abstract[8]|abstract[11]	new[7]|new[8]|new[11]	_	_
2-30	220-221	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-31	222-228	repair	abstract[7]|abstract[8]|abstract	new[7]|new[8]|new	_	_
2-32	229-230	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-33	231-234	and	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-34	235-247	regeneration	abstract[7]|abstract[8]|event	new[7]|new[8]|new	_	_
2-35	248-250	as	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-36	251-255	well	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-37	256-258	as	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-38	259-266	altered	abstract[7]|abstract[8]|abstract[14]	new[7]|new[8]|new[14]	_	_
2-39	267-273	inter-	abstract[7]|abstract[8]|abstract[14]	new[7]|new[8]|new[14]	_	_
2-40	274-277	and	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-41	278-291	intracellular	abstract[7]|abstract[8]|abstract[15]	new[7]|new[8]|new[15]	_	_
2-42	292-305	communication	abstract[7]|abstract[8]|abstract[15]	new[7]|new[8]|new[15]	_	_
2-43	306-307	.	_	_	_	_

#Text=Typical alterations detectable in aged tissues are increased concentrations of reactive oxygen species ( ROS ) and concomitant increased DNA-damage , lipid and protein oxidation .
3-1	308-315	Typical	abstract[16]	new[16]	coref	3-8[18_16]
3-2	316-327	alterations	abstract[16]	new[16]	_	_
3-3	328-338	detectable	_	_	_	_
3-4	339-341	in	_	_	_	_
3-5	342-346	aged	object[17]	new[17]	coref	11-11[0_17]
3-6	347-354	tissues	object[17]	new[17]	_	_
3-7	355-358	are	_	_	_	_
3-8	359-368	increased	abstract[18]	giv[18]	_	_
3-9	369-383	concentrations	abstract[18]	giv[18]	_	_
3-10	384-386	of	abstract[18]	giv[18]	_	_
3-11	387-395	reactive	abstract[18]|abstract[20]	giv[18]|new[20]	_	_
3-12	396-402	oxygen	abstract[18]|substance|abstract[20]	giv[18]|new|new[20]	_	_
3-13	403-410	species	abstract[18]|abstract[20]	giv[18]|new[20]	_	_
3-14	411-412	(	_	_	_	_
3-15	413-416	ROS	substance	new	_	_
3-16	417-418	)	_	_	_	_
3-17	419-422	and	_	_	_	_
3-18	423-434	concomitant	substance[22]	new[22]	_	_
3-19	435-444	increased	substance[22]	new[22]	_	_
3-20	445-455	DNA-damage	substance[22]	new[22]	_	_
3-21	456-457	,	_	_	_	_
3-22	458-463	lipid	substance	new	coref	13-10
3-23	464-467	and	_	_	_	_
3-24	468-475	protein	substance|abstract[25]	new|new[25]	ana|coref|ana|coref	4-2[0_25]|4-9|4-2[0_25]|4-9
3-25	476-485	oxidation	abstract[25]	new[25]	_	_
3-26	486-487	.	_	_	_	_

#Text=Often this is accompanied by accumulation of insoluble protein aggregates ( lipofuscin ) at least partially as a consequence of impaired proteasome function .
4-1	488-493	Often	_	_	_	_
4-2	494-498	this	abstract	giv	coref	8-12[57_0]
4-3	499-501	is	_	_	_	_
4-4	502-513	accompanied	_	_	_	_
4-5	514-516	by	_	_	_	_
4-6	517-529	accumulation	abstract[27]	giv[27]	_	_
4-7	530-532	of	abstract[27]	giv[27]	_	_
4-8	533-542	insoluble	abstract[27]|abstract[29]	giv[27]|new[29]	coref	13-29[104_29]
4-9	543-550	protein	abstract[27]|substance|abstract[29]	giv[27]|giv|new[29]	coref	13-30
4-10	551-561	aggregates	abstract[27]|abstract[29]	giv[27]|new[29]	_	_
4-11	562-563	(	_	_	_	_
4-12	564-574	lipofuscin	person	new	_	_
4-13	575-576	)	_	_	_	_
4-14	577-579	at	_	_	_	_
4-15	580-585	least	_	_	_	_
4-16	586-595	partially	_	_	_	_
4-17	596-598	as	_	_	_	_
4-18	599-600	a	_	_	_	_
4-19	601-612	consequence	_	_	_	_
4-20	613-615	of	_	_	_	_
4-21	616-624	impaired	abstract[32]	new[32]	coref	5-13[35_32]
4-22	625-635	proteasome	object|abstract[32]	new|new[32]	_	_
4-23	636-644	function	abstract[32]	new[32]	_	_
4-24	645-646	.	_	_	_	_

#Text=In addition , glycation was reported to contribute to limited degradation and function of proteins .
5-1	647-649	In	_	_	_	_
5-2	650-658	addition	_	_	_	_
5-3	659-660	,	_	_	_	_
5-4	661-670	glycation	substance	new	coref	6-1
5-5	671-674	was	_	_	_	_
5-6	675-683	reported	_	_	_	_
5-7	684-686	to	_	_	_	_
5-8	687-697	contribute	_	_	_	_
5-9	698-700	to	_	_	_	_
5-10	701-708	limited	abstract[34]	new[34]	_	_
5-11	709-720	degradation	abstract[34]	new[34]	_	_
5-12	721-724	and	_	_	_	_
5-13	725-733	function	abstract[35]	giv[35]	_	_
5-14	734-736	of	abstract[35]	giv[35]	_	_
5-15	737-745	proteins	abstract[35]|substance	giv[35]|new	coref	13-25
5-16	746-747	.	_	_	_	_

#Text=Glycation represents an important posttranslational modification that significantly increases during aging and results in the formation of advanced glycation end products ( AGEs ) .
6-1	748-757	Glycation	substance	giv	coref	6-19
6-2	758-768	represents	_	_	_	_
6-3	769-771	an	abstract[38]	new[38]	coref	17-4[134_38]
6-4	772-781	important	abstract[38]	new[38]	_	_
6-5	782-799	posttranslational	abstract[38]	new[38]	_	_
6-6	800-812	modification	abstract[38]	new[38]	_	_
6-7	813-817	that	_	_	_	_
6-8	818-831	significantly	_	_	_	_
6-9	832-841	increases	_	_	_	_
6-10	842-848	during	_	_	_	_
6-11	849-854	aging	abstract	new	coref	20-16
6-12	855-858	and	_	_	_	_
6-13	859-866	results	abstract	new	_	_
6-14	867-869	in	_	_	_	_
6-15	870-873	the	abstract[41]	new[41]	_	_
6-16	874-883	formation	abstract[41]	new[41]	_	_
6-17	884-886	of	abstract[41]	new[41]	_	_
6-18	887-895	advanced	abstract[41]|object[44]	new[41]|new[44]	appos	6-23[0_44]
6-19	896-905	glycation	abstract[41]|abstract|object[44]	new[41]|giv|new[44]	coref	10-23
6-20	906-909	end	abstract[41]|abstract|object[44]	new[41]|new|new[44]	coref	17-17
6-21	910-918	products	abstract[41]|object[44]	new[41]|new[44]	_	_
6-22	919-920	(	_	_	_	_
6-23	921-925	AGEs	object	giv	coref	7-1
6-24	926-927	)	_	_	_	_
6-25	928-929	.	_	_	_	_

#Text=AGEs are generated by an initial non-enzymatic reaction of amino groups with reactive carbonyl groups of monosaccharides known as the Maillard reaction , thereby forming Schiff-base adducts .
7-1	930-934	AGEs	object	giv	coref	8-7[56_0]
7-2	935-938	are	_	_	_	_
7-3	939-948	generated	_	_	_	_
7-4	949-951	by	_	_	_	_
7-5	952-954	an	event[47]	new[47]	_	_
7-6	955-962	initial	event[47]	new[47]	_	_
7-7	963-976	non-enzymatic	event[47]	new[47]	_	_
7-8	977-985	reaction	event[47]	new[47]	_	_
7-9	986-988	of	event[47]	new[47]	_	_
7-10	989-994	amino	event[47]|person[48]	new[47]|new[48]	_	_
7-11	995-1001	groups	event[47]|person[48]	new[47]|new[48]	_	_
7-12	1002-1006	with	event[47]|person[48]	new[47]|new[48]	_	_
7-13	1007-1015	reactive	event[47]|person[48]|person[50]	new[47]|new[48]|new[50]	_	_
7-14	1016-1024	carbonyl	event[47]|person[48]|organization|person[50]	new[47]|new[48]|new|new[50]	_	_
7-15	1025-1031	groups	event[47]|person[48]|person[50]	new[47]|new[48]|new[50]	_	_
7-16	1032-1034	of	event[47]|person[48]|person[50]	new[47]|new[48]|new[50]	_	_
7-17	1035-1050	monosaccharides	event[47]|person[48]|person[50]|substance	new[47]|new[48]|new[50]|new	_	_
7-18	1051-1056	known	_	_	_	_
7-19	1057-1059	as	_	_	_	_
7-20	1060-1063	the	_	_	_	_
7-21	1064-1072	Maillard	person	new	_	_
7-22	1073-1081	reaction	_	_	_	_
7-23	1082-1083	,	_	_	_	_
7-24	1084-1091	thereby	_	_	_	_
7-25	1092-1099	forming	_	_	_	_
7-26	1100-1111	Schiff-base	abstract[53]	new[53]	coref	8-1[54_53]
7-27	1112-1119	adducts	abstract[53]	new[53]	_	_
7-28	1120-1121	.	_	_	_	_

#Text=These adducts are subsequently rearranged to so-called Amadori products which undergo further oxidation and dehydration reactions leading to a large group of heterogeneous products .
8-1	1122-1127	These	abstract[54]	giv[54]	coref	9-10[0_54]
8-2	1128-1135	adducts	abstract[54]	giv[54]	_	_
8-3	1136-1139	are	_	_	_	_
8-4	1140-1152	subsequently	_	_	_	_
8-5	1153-1163	rearranged	_	_	_	_
8-6	1164-1166	to	_	_	_	_
8-7	1167-1176	so-called	object[56]	giv[56]	coref	8-23[61_56]
8-8	1177-1184	Amadori	person|object[56]	new|giv[56]	coref	9-7
8-9	1185-1193	products	object[56]	giv[56]	_	_
8-10	1194-1199	which	_	_	_	_
8-11	1200-1207	undergo	_	_	_	_
8-12	1208-1215	further	abstract[57]	giv[57]	_	_
8-13	1216-1225	oxidation	abstract[57]	giv[57]	_	_
8-14	1226-1229	and	_	_	_	_
8-15	1230-1241	dehydration	abstract|event[59]	new|new[59]	_	_
8-16	1242-1251	reactions	event[59]	new[59]	_	_
8-17	1252-1259	leading	_	_	_	_
8-18	1260-1262	to	_	_	_	_
8-19	1263-1264	a	abstract[60]	new[60]	_	_
8-20	1265-1270	large	abstract[60]	new[60]	_	_
8-21	1271-1276	group	abstract[60]	new[60]	_	_
8-22	1277-1279	of	abstract[60]	new[60]	_	_
8-23	1280-1293	heterogeneous	abstract[60]|object[61]	new[60]|giv[61]	coref	9-6[64_61]
8-24	1294-1302	products	abstract[60]|object[61]	new[60]|giv[61]	_	_
8-25	1303-1304	.	_	_	_	_

#Text=Up to the stage of the Amadori products , adducts are basically reversible .
9-1	1305-1307	Up	_	_	_	_
9-2	1308-1310	to	_	_	_	_
9-3	1311-1314	the	time[62]	new[62]	_	_
9-4	1315-1320	stage	time[62]	new[62]	_	_
9-5	1321-1323	of	time[62]	new[62]	_	_
9-6	1324-1327	the	time[62]|object[64]	new[62]|giv[64]	coref	11-1[74_64]
9-7	1328-1335	Amadori	time[62]|person|object[64]	new[62]|giv|giv[64]	_	_
9-8	1336-1344	products	time[62]|object[64]	new[62]|giv[64]	_	_
9-9	1345-1346	,	_	_	_	_
9-10	1347-1354	adducts	abstract	giv	_	_
9-11	1355-1358	are	_	_	_	_
9-12	1359-1368	basically	_	_	_	_
9-13	1369-1379	reversible	_	_	_	_
9-14	1380-1381	.	_	_	_	_

#Text=Preferentially lysine residues , but also other amino acids including arginine , histidine , tryptophan , or cysteine , are modified by glycation .
10-1	1382-1396	Preferentially	substance[67]	new[67]	_	_
10-2	1397-1403	lysine	abstract|substance[67]	new|new[67]	_	_
10-3	1404-1412	residues	substance[67]	new[67]	_	_
10-4	1413-1414	,	_	_	_	_
10-5	1415-1418	but	_	_	_	_
10-6	1419-1423	also	_	_	_	_
10-7	1424-1429	other	substance[68]	new[68]	_	_
10-8	1430-1435	amino	substance[68]	new[68]	_	_
10-9	1436-1441	acids	substance[68]	new[68]	_	_
10-10	1442-1451	including	substance[68]	new[68]	_	_
10-11	1452-1460	arginine	substance[68]|substance	new[68]|new	_	_
10-12	1461-1462	,	substance[68]	new[68]	_	_
10-13	1463-1472	histidine	substance[68]|substance	new[68]|new	_	_
10-14	1473-1474	,	substance[68]	new[68]	_	_
10-15	1475-1485	tryptophan	substance[68]|substance	new[68]|new	_	_
10-16	1486-1487	,	substance[68]	new[68]	_	_
10-17	1488-1490	or	substance[68]	new[68]	_	_
10-18	1491-1499	cysteine	substance[68]|substance	new[68]|new	_	_
10-19	1500-1501	,	_	_	_	_
10-20	1502-1505	are	_	_	_	_
10-21	1506-1514	modified	_	_	_	_
10-22	1515-1517	by	_	_	_	_
10-23	1518-1527	glycation	substance	giv	coref	15-8
10-24	1528-1529	.	_	_	_	_

#Text=The most prominent and well-known AGEs identified in cells and tissues are carboxymethyllysine ( CML ) , carboxyethyllysine ( CEL ) , pentosidine , and desoxyglucosone .
11-1	1530-1533	The	object[74]	giv[74]	coref	12-3[81_74]
11-2	1534-1538	most	object[74]	giv[74]	_	_
11-3	1539-1548	prominent	object[74]	giv[74]	_	_
11-4	1549-1552	and	object[74]	giv[74]	_	_
11-5	1553-1563	well-known	object[74]	giv[74]	_	_
11-6	1564-1568	AGEs	object[74]	giv[74]	_	_
11-7	1569-1579	identified	_	_	_	_
11-8	1580-1582	in	_	_	_	_
11-9	1583-1588	cells	object	new	_	_
11-10	1589-1592	and	_	_	_	_
11-11	1593-1600	tissues	object	giv	coref	14-20[111_0]
11-12	1601-1604	are	_	_	_	_
11-13	1605-1624	carboxymethyllysine	_	_	_	_
11-14	1625-1626	(	abstract[77]	new[77]	_	_
11-15	1627-1630	CML	abstract[77]	new[77]	_	_
11-16	1631-1632	)	abstract[77]	new[77]	_	_
11-17	1633-1634	,	abstract[77]	new[77]	_	_
11-18	1635-1653	carboxyethyllysine	abstract[77]	new[77]	_	_
11-19	1654-1655	(	abstract[77]	new[77]	_	_
11-20	1656-1659	CEL	abstract[77]|abstract	new[77]|new	_	_
11-21	1660-1661	)	abstract[77]	new[77]	_	_
11-22	1662-1663	,	abstract[77]	new[77]	_	_
11-23	1664-1675	pentosidine	abstract[77]|substance	new[77]|new	_	_
11-24	1676-1677	,	abstract[77]	new[77]	_	_
11-25	1678-1681	and	abstract[77]	new[77]	_	_
11-26	1682-1697	desoxyglucosone	abstract[77]|substance	new[77]|new	_	_
11-27	1698-1699	.	_	_	_	_

#Text=Physiologically , these AGEs are formed in response to so-called “ dicarbonyl stress ” as given under conditions of hyperglycemia or in the presence of highly reactive α-dicarbonyls ( α-DCs ) such as glyoxal ( GO ) , methylglyoxal ( MGO ) or 3-deoxyglucosone .
12-1	1700-1715	Physiologically	_	_	_	_
12-2	1716-1717	,	_	_	_	_
12-3	1718-1723	these	object[81]	giv[81]	coref	13-20[101_81]
12-4	1724-1728	AGEs	object[81]	giv[81]	_	_
12-5	1729-1732	are	_	_	_	_
12-6	1733-1739	formed	_	_	_	_
12-7	1740-1742	in	_	_	_	_
12-8	1743-1751	response	abstract[82]	giv[82]	_	_
12-9	1752-1754	to	abstract[82]	giv[82]	_	_
12-10	1755-1764	so-called	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-11	1765-1766	“	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-12	1767-1777	dicarbonyl	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-13	1778-1784	stress	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-14	1785-1786	”	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-15	1787-1789	as	_	_	_	_
12-16	1790-1795	given	_	_	_	_
12-17	1796-1801	under	_	_	_	_
12-18	1802-1812	conditions	abstract[84]	new[84]	_	_
12-19	1813-1815	of	abstract[84]	new[84]	_	_
12-20	1816-1829	hyperglycemia	abstract[84]|abstract	new[84]|new	_	_
12-21	1830-1832	or	_	_	_	_
12-22	1833-1835	in	_	_	_	_
12-23	1836-1839	the	abstract[86]	new[86]	_	_
12-24	1840-1848	presence	abstract[86]	new[86]	_	_
12-25	1849-1851	of	abstract[86]	new[86]	_	_
12-26	1852-1858	highly	abstract[86]|substance[87]	new[86]|new[87]	appos	12-30[0_87]
12-27	1859-1867	reactive	abstract[86]|substance[87]	new[86]|new[87]	_	_
12-28	1868-1881	α-dicarbonyls	abstract[86]|substance[87]	new[86]|new[87]	_	_
12-29	1882-1883	(	_	_	_	_
12-30	1884-1889	α-DCs	substance	giv	coref	13-1[93_0]
12-31	1890-1891	)	_	_	_	_
12-32	1892-1896	such	_	_	_	_
12-33	1897-1899	as	_	_	_	_
12-34	1900-1907	glyoxal	substance	new	_	_
12-35	1908-1909	(	_	_	_	_
12-36	1910-1912	GO	_	_	_	_
12-37	1913-1914	)	_	_	_	_
12-38	1915-1916	,	_	_	_	_
12-39	1917-1930	methylglyoxal	substance	new	appos	12-41
12-40	1931-1932	(	_	_	_	_
12-41	1933-1936	MGO	substance	giv	_	_
12-42	1937-1938	)	_	_	_	_
12-43	1939-1941	or	_	_	_	_
12-44	1942-1958	3-deoxyglucosone	substance	new	_	_
12-45	1959-1960	.	_	_	_	_

#Text=These α-DCs are inevitable byproducts of anaerobic glycolysis and lipid peroxidation and in consequence , induce the formation of highly stable AGEs which crosslink proteins and lead to protease-resistant protein aggregates .
13-1	1961-1966	These	substance[93]	giv[93]	_	_
13-2	1967-1972	α-DCs	substance[93]	giv[93]	_	_
13-3	1973-1976	are	_	_	_	_
13-4	1977-1987	inevitable	_	_	_	_
13-5	1988-1998	byproducts	substance[94]	new[94]	_	_
13-6	1999-2001	of	substance[94]	new[94]	_	_
13-7	2002-2011	anaerobic	substance[94]|abstract|substance[96]	new[94]|new|new[96]	_	_
13-8	2012-2022	glycolysis	substance[94]|substance[96]	new[94]|new[96]	_	_
13-9	2023-2026	and	substance[94]	new[94]	_	_
13-10	2027-2032	lipid	substance[94]|person|substance[98]	new[94]|giv|new[98]	_	_
13-11	2033-2045	peroxidation	substance[94]|substance[98]	new[94]|new[98]	_	_
13-12	2046-2049	and	_	_	_	_
13-13	2050-2052	in	_	_	_	_
13-14	2053-2064	consequence	abstract	new	_	_
13-15	2065-2066	,	_	_	_	_
13-16	2067-2073	induce	_	_	_	_
13-17	2074-2077	the	event[100]	new[100]	_	_
13-18	2078-2087	formation	event[100]	new[100]	_	_
13-19	2088-2090	of	event[100]	new[100]	_	_
13-20	2091-2097	highly	event[100]|object[101]	new[100]|giv[101]	coref	15-10[0_101]
13-21	2098-2104	stable	event[100]|object[101]	new[100]|giv[101]	_	_
13-22	2105-2109	AGEs	event[100]|object[101]	new[100]|giv[101]	_	_
13-23	2110-2115	which	_	_	_	_
13-24	2116-2125	crosslink	_	_	_	_
13-25	2126-2134	proteins	substance	giv	coref	14-8[108_0]
13-26	2135-2138	and	_	_	_	_
13-27	2139-2143	lead	_	_	_	_
13-28	2144-2146	to	_	_	_	_
13-29	2147-2165	protease-resistant	abstract[104]	giv[104]	_	_
13-30	2166-2173	protein	substance|abstract[104]	giv|giv[104]	_	_
13-31	2174-2184	aggregates	abstract[104]	giv[104]	_	_
13-32	2185-2186	.	_	_	_	_

#Text=In this context , glycation-induced modifications of extracellular matrix proteins resulting in intermolecular crosslinks lead to increased stiffness of tissues and vessels and affect cell migration .
14-1	2187-2189	In	_	_	_	_
14-2	2190-2194	this	abstract[105]	new[105]	_	_
14-3	2195-2202	context	abstract[105]	new[105]	_	_
14-4	2203-2204	,	_	_	_	_
14-5	2205-2222	glycation-induced	abstract[106]	new[106]	coref	28-19[222_106]
14-6	2223-2236	modifications	abstract[106]	new[106]	_	_
14-7	2237-2239	of	abstract[106]	new[106]	_	_
14-8	2240-2253	extracellular	abstract[106]|substance[108]	new[106]|giv[108]	coref	28-14[221_108]
14-9	2254-2260	matrix	abstract[106]|abstract|substance[108]	new[106]|new|giv[108]	_	_
14-10	2261-2269	proteins	abstract[106]|substance[108]	new[106]|giv[108]	_	_
14-11	2270-2279	resulting	_	_	_	_
14-12	2280-2282	in	_	_	_	_
14-13	2283-2297	intermolecular	object[109]	new[109]	_	_
14-14	2298-2308	crosslinks	object[109]	new[109]	_	_
14-15	2309-2313	lead	_	_	_	_
14-16	2314-2316	to	_	_	_	_
14-17	2317-2326	increased	event[110]	new[110]	_	_
14-18	2327-2336	stiffness	event[110]	new[110]	_	_
14-19	2337-2339	of	event[110]	new[110]	_	_
14-20	2340-2347	tissues	event[110]|object[111]	new[110]|giv[111]	_	_
14-21	2348-2351	and	event[110]|object[111]	new[110]|giv[111]	_	_
14-22	2352-2359	vessels	event[110]|object[111]|object	new[110]|giv[111]|new	_	_
14-23	2360-2363	and	_	_	_	_
14-24	2364-2370	affect	_	_	_	_
14-25	2371-2375	cell	place|event[114]	new|new[114]	_	_
14-26	2376-2385	migration	event[114]	new[114]	_	_
14-27	2386-2387	.	_	_	_	_

#Text=Furthermore , there is clear evidence that glycation and AGEs lead to mitochondrial dysfunction and impaired immune responses .
15-1	2388-2399	Furthermore	_	_	_	_
15-2	2400-2401	,	_	_	_	_
15-3	2402-2407	there	_	_	_	_
15-4	2408-2410	is	_	_	_	_
15-5	2411-2416	clear	abstract[115]	new[115]	coref	22-5[175_115]
15-6	2417-2425	evidence	abstract[115]	new[115]	_	_
15-7	2426-2430	that	_	_	_	_
15-8	2431-2440	glycation	substance	giv	coref	16-1[122_0]
15-9	2441-2444	and	_	_	_	_
15-10	2445-2449	AGEs	object	giv	coref	17-15[139_0]
15-11	2450-2454	lead	_	_	_	_
15-12	2455-2457	to	_	_	_	_
15-13	2458-2471	mitochondrial	abstract|abstract[119]	new|new[119]	_	_
15-14	2472-2483	dysfunction	abstract[119]	new[119]	_	_
15-15	2484-2487	and	_	_	_	_
15-16	2488-2496	impaired	abstract[121]	new[121]	_	_
15-17	2497-2503	immune	abstract|abstract[121]	giv|new[121]	_	_
15-18	2504-2513	responses	abstract[121]	new[121]	_	_
15-19	2514-2515	.	_	_	_	_

#Text=Glycation of growth factors such as platelet-derived growth factor ( PDGF ) and insulin , as well as receptors such as nerve growth factor ( NGF)-receptor , were reported to affect signaling functions .
16-1	2516-2525	Glycation	substance[122]	giv[122]	coref	17-16[0_122]
16-2	2526-2528	of	substance[122]	giv[122]	_	_
16-3	2529-2535	growth	substance[122]|abstract[123]	giv[122]|new[123]	coref	25-32[202_123]
16-4	2536-2543	factors	substance[122]|abstract[123]	giv[122]|new[123]	_	_
16-5	2544-2548	such	substance[122]|abstract[123]	giv[122]|new[123]	_	_
16-6	2549-2551	as	substance[122]|abstract[123]	giv[122]|new[123]	_	_
16-7	2552-2568	platelet-derived	substance[122]|abstract[123]|abstract[125]	giv[122]|new[123]|new[125]	appos	16-11[0_125]
16-8	2569-2575	growth	substance[122]|abstract[123]|abstract|abstract[125]	giv[122]|new[123]|new|new[125]	coref	16-23
16-9	2576-2582	factor	substance[122]|abstract[123]|abstract[125]	giv[122]|new[123]|new[125]	_	_
16-10	2583-2584	(	_	_	_	_
16-11	2585-2589	PDGF	abstract	giv	coref	16-22[130_0]
16-12	2590-2591	)	_	_	_	_
16-13	2592-2595	and	_	_	_	_
16-14	2596-2603	insulin	substance	new	_	_
16-15	2604-2605	,	_	_	_	_
16-16	2606-2608	as	_	_	_	_
16-17	2609-2613	well	_	_	_	_
16-18	2614-2616	as	_	_	_	_
16-19	2617-2626	receptors	substance[128]	new[128]	_	_
16-20	2627-2631	such	substance[128]	new[128]	_	_
16-21	2632-2634	as	substance[128]	new[128]	_	_
16-22	2635-2640	nerve	substance[128]|abstract[130]	new[128]|giv[130]	coref	25-25[199_130]
16-23	2641-2647	growth	substance[128]|abstract|abstract[130]	new[128]|giv|giv[130]	_	_
16-24	2648-2654	factor	substance[128]|abstract[130]	new[128]|giv[130]	_	_
16-25	2655-2656	(	_	_	_	_
16-26	2657-2670	NGF)-receptor	person	new	_	_
16-27	2671-2672	,	_	_	_	_
16-28	2673-2677	were	_	_	_	_
16-29	2678-2686	reported	_	_	_	_
16-30	2687-2689	to	_	_	_	_
16-31	2690-2696	affect	_	_	_	_
16-32	2697-2706	signaling	abstract[132]	new[132]	_	_
16-33	2707-2716	functions	abstract[132]	new[132]	_	_
16-34	2717-2718	.	_	_	_	_

#Text=In addition , AGE modification itself can induce signaling mainly through the receptor for advanced glycation end products ( RAGE ) , a multi-ligand transmembrane receptor containing immunoglobulin domains .
17-1	2719-2721	In	_	_	_	_
17-2	2722-2730	addition	_	_	_	_
17-3	2731-2732	,	_	_	_	_
17-4	2733-2736	AGE	substance|abstract[134]	new|giv[134]	ana|ana	17-6[0_134]|17-6[0_134]
17-5	2737-2749	modification	abstract[134]	giv[134]	_	_
17-6	2750-2756	itself	abstract	giv	_	_
17-7	2757-2760	can	_	_	_	_
17-8	2761-2767	induce	_	_	_	_
17-9	2768-2777	signaling	_	_	_	_
17-10	2778-2784	mainly	_	_	_	_
17-11	2785-2792	through	_	_	_	_
17-12	2793-2796	the	substance[136]	new[136]	coref	17-23[141_136]
17-13	2797-2805	receptor	substance[136]	new[136]	_	_
17-14	2806-2809	for	substance[136]	new[136]	_	_
17-15	2810-2818	advanced	substance[136]|object[139]	new[136]|giv[139]	coref	19-6[157_139]
17-16	2819-2828	glycation	substance[136]|abstract|object[139]	new[136]|giv|giv[139]	coref	28-23
17-17	2829-2832	end	substance[136]|abstract|object[139]	new[136]|giv|giv[139]	_	_
17-18	2833-2841	products	substance[136]|object[139]	new[136]|giv[139]	_	_
17-19	2842-2843	(	_	_	_	_
17-20	2844-2848	RAGE	abstract	new	coref	19-8
17-21	2849-2850	)	_	_	_	_
17-22	2851-2852	,	_	_	_	_
17-23	2853-2854	a	substance[141]	giv[141]	_	_
17-24	2855-2867	multi-ligand	substance[141]	giv[141]	_	_
17-25	2868-2881	transmembrane	substance[141]	giv[141]	_	_
17-26	2882-2890	receptor	substance[141]	giv[141]	_	_
17-27	2891-2901	containing	_	_	_	_
17-28	2902-2916	immunoglobulin	person|abstract[143]	new|new[143]	_	_
17-29	2917-2924	domains	abstract[143]	new[143]	_	_
17-30	2925-2926	.	_	_	_	_

#Text=RAGE-induced signaling contributes to aging-related inflammation and metabolic diseases by modulation of multiple pathways including phosphoinositide 3-kinase ( PI3K ) , Erk1/2 and Wnt signaling .
18-1	2927-2939	RAGE-induced	abstract[144]	new[144]	coref	18-22[155_144]
18-2	2940-2949	signaling	abstract[144]	new[144]	_	_
18-3	2950-2961	contributes	_	_	_	_
18-4	2962-2964	to	_	_	_	_
18-5	2965-2978	aging-related	abstract[145]	new[145]	_	_
18-6	2979-2991	inflammation	abstract[145]	new[145]	_	_
18-7	2992-2995	and	_	_	_	_
18-8	2996-3005	metabolic	object|abstract[147]	new|new[147]	_	_
18-9	3006-3014	diseases	abstract[147]	new[147]	_	_
18-10	3015-3017	by	_	_	_	_
18-11	3018-3028	modulation	abstract[148]	new[148]	_	_
18-12	3029-3031	of	abstract[148]	new[148]	_	_
18-13	3032-3040	multiple	abstract[148]|place[149]	new[148]|new[149]	coref	21-12[170_149]
18-14	3041-3049	pathways	abstract[148]|place[149]	new[148]|new[149]	_	_
18-15	3050-3059	including	abstract[148]|place[149]	new[148]|new[149]	_	_
18-16	3060-3076	phosphoinositide	abstract[148]|place[149]|place|abstract[151]	new[148]|new[149]|new|new[151]	appos|appos	18-19[0_151]|18-19[0_151]
18-17	3077-3085	3-kinase	abstract[148]|place[149]|abstract[151]	new[148]|new[149]|new[151]	_	_
18-18	3086-3087	(	_	_	_	_
18-19	3088-3092	PI3K	abstract	giv	_	_
18-20	3093-3094	)	_	_	_	_
18-21	3095-3096	,	_	_	_	_
18-22	3097-3103	Erk1/2	abstract|abstract[155]	new|giv[155]	coref|coref	19-8[159_155]|19-8[159_155]
18-23	3104-3107	and	abstract[155]	giv[155]	_	_
18-24	3108-3111	Wnt	abstract|abstract[155]	new|giv[155]	coref	20-13
18-25	3112-3121	signaling	abstract[155]	giv[155]	_	_
18-26	3122-3123	.	_	_	_	_

#Text=However , the outcome of AGEs and RAGE signaling appears to be a double-edged sword with degenerative and protective effects .
19-1	3124-3131	However	_	_	_	_
19-2	3132-3133	,	_	_	_	_
19-3	3134-3137	the	abstract[156]	new[156]	_	_
19-4	3138-3145	outcome	abstract[156]	new[156]	_	_
19-5	3146-3148	of	abstract[156]	new[156]	_	_
19-6	3149-3153	AGEs	abstract[156]|object[157]	new[156]|giv[157]	_	_
19-7	3154-3157	and	abstract[156]|object[157]	new[156]|giv[157]	_	_
19-8	3158-3162	RAGE	abstract[156]|object[157]|abstract|abstract[159]	new[156]|giv[157]|giv|giv[159]	ana|ana	20-1[0_159]|20-1[0_159]
19-9	3163-3172	signaling	abstract[156]|object[157]|abstract[159]	new[156]|giv[157]|giv[159]	_	_
19-10	3173-3180	appears	_	_	_	_
19-11	3181-3183	to	_	_	_	_
19-12	3184-3186	be	_	_	_	_
19-13	3187-3188	a	abstract[160]	new[160]	_	_
19-14	3189-3201	double-edged	abstract[160]	new[160]	_	_
19-15	3202-3207	sword	abstract[160]	new[160]	_	_
19-16	3208-3212	with	abstract[160]	new[160]	_	_
19-17	3213-3225	degenerative	abstract[160]|abstract[161]	new[160]|new[161]	coref	29-17[231_161]
19-18	3226-3229	and	abstract[160]|abstract[161]	new[160]|new[161]	_	_
19-19	3230-3240	protective	abstract[160]|abstract[161]	new[160]|new[161]	_	_
19-20	3241-3248	effects	abstract[160]|abstract[161]	new[160]|new[161]	_	_
19-21	3249-3250	.	_	_	_	_

#Text=This also appears to be true in respect to the role of Wnt signaling in aging .
20-1	3251-3255	This	abstract	giv	coref	21-4
20-2	3256-3260	also	_	_	_	_
20-3	3261-3268	appears	_	_	_	_
20-4	3269-3271	to	_	_	_	_
20-5	3272-3274	be	_	_	_	_
20-6	3275-3279	true	_	_	_	_
20-7	3280-3282	in	_	_	_	_
20-8	3283-3290	respect	abstract[163]	new[163]	_	_
20-9	3291-3293	to	abstract[163]	new[163]	_	_
20-10	3294-3297	the	abstract[163]|abstract[164]	new[163]|new[164]	_	_
20-11	3298-3302	role	abstract[163]|abstract[164]	new[163]|new[164]	_	_
20-12	3303-3305	of	abstract[163]|abstract[164]	new[163]|new[164]	_	_
20-13	3306-3309	Wnt	abstract[163]|abstract[164]|abstract	new[163]|new[164]|giv	coref	22-12
20-14	3310-3319	signaling	_	_	_	_
20-15	3320-3322	in	_	_	_	_
20-16	3323-3328	aging	abstract	giv	_	_
20-17	3329-3330	.	_	_	_	_

#Text=The canonical Wnt/β-catenin signaling cascade acts as a pivotal regulator of developmental and pathogenesis pathways including cell stemness maintenance/differentiation , carcinogenesis , and aging-related phenotypes .
21-1	3331-3334	The	abstract[169]	new[169]	_	_
21-2	3335-3344	canonical	abstract[169]	new[169]	_	_
21-3	3345-3358	Wnt/β-catenin	abstract|abstract[169]	new|new[169]	_	_
21-4	3359-3368	signaling	abstract|abstract[169]	giv|new[169]	coref	23-5
21-5	3369-3376	cascade	abstract[169]	new[169]	_	_
21-6	3377-3381	acts	_	_	_	_
21-7	3382-3384	as	_	_	_	_
21-8	3385-3386	a	_	_	_	_
21-9	3387-3394	pivotal	_	_	_	_
21-10	3395-3404	regulator	_	_	_	_
21-11	3405-3407	of	_	_	_	_
21-12	3408-3421	developmental	place[170]	giv[170]	_	_
21-13	3422-3425	and	place[170]	giv[170]	_	_
21-14	3426-3438	pathogenesis	place[170]	giv[170]	_	_
21-15	3439-3447	pathways	place[170]	giv[170]	_	_
21-16	3448-3457	including	place[170]	giv[170]	_	_
21-17	3458-3462	cell	place[170]|abstract[172]	giv[170]|new[172]	_	_
21-18	3463-3471	stemness	place[170]|abstract|abstract[172]	giv[170]|new|new[172]	_	_
21-19	3472-3499	maintenance/differentiation	place[170]|abstract[172]	giv[170]|new[172]	_	_
21-20	3500-3501	,	place[170]	giv[170]	_	_
21-21	3502-3516	carcinogenesis	place[170]|abstract	giv[170]|new	_	_
21-22	3517-3518	,	place[170]	giv[170]	_	_
21-23	3519-3522	and	place[170]	giv[170]	_	_
21-24	3523-3536	aging-related	place[170]|abstract[174]	giv[170]|new[174]	_	_
21-25	3537-3547	phenotypes	place[170]|abstract[174]	giv[170]|new[174]	_	_
21-26	3548-3549	.	_	_	_	_

#Text=Moreover , there is clear evidence for a role of the Wnt pathway in mitochondrial respiratory capacity and metabolic homeostasis , especially of glucose metabolism .
22-1	3550-3558	Moreover	_	_	_	_
22-2	3559-3560	,	_	_	_	_
22-3	3561-3566	there	_	_	_	_
22-4	3567-3569	is	_	_	_	_
22-5	3570-3575	clear	abstract[175]	giv[175]	_	_
22-6	3576-3584	evidence	abstract[175]	giv[175]	_	_
22-7	3585-3588	for	abstract[175]	giv[175]	_	_
22-8	3589-3590	a	abstract[175]|abstract[176]	giv[175]|new[176]	_	_
22-9	3591-3595	role	abstract[175]|abstract[176]	giv[175]|new[176]	_	_
22-10	3596-3598	of	abstract[175]|abstract[176]	giv[175]|new[176]	_	_
22-11	3599-3602	the	abstract[175]|abstract[176]|place[178]	giv[175]|new[176]|new[178]	coref	23-2[185_178]
22-12	3603-3606	Wnt	abstract[175]|abstract[176]|abstract|place[178]	giv[175]|new[176]|giv|new[178]	coref	23-4
22-13	3607-3614	pathway	abstract[175]|abstract[176]|place[178]	giv[175]|new[176]|new[178]	_	_
22-14	3615-3617	in	abstract[175]|abstract[176]|place[178]	giv[175]|new[176]|new[178]	_	_
22-15	3618-3631	mitochondrial	abstract[175]|abstract[176]|place[178]|abstract[179]	giv[175]|new[176]|new[178]|new[179]	_	_
22-16	3632-3643	respiratory	abstract[175]|abstract[176]|place[178]|abstract[179]	giv[175]|new[176]|new[178]|new[179]	_	_
22-17	3644-3652	capacity	abstract[175]|abstract[176]|place[178]|abstract[179]	giv[175]|new[176]|new[178]|new[179]	_	_
22-18	3653-3656	and	abstract[175]|abstract[176]|place[178]	giv[175]|new[176]|new[178]	_	_
22-19	3657-3666	metabolic	abstract[175]|abstract[176]|place[178]|abstract[180]	giv[175]|new[176]|new[178]|new[180]	_	_
22-20	3667-3678	homeostasis	abstract[175]|abstract[176]|place[178]|abstract[180]	giv[175]|new[176]|new[178]|new[180]	_	_
22-21	3679-3680	,	abstract[175]|abstract[176]|place[178]|abstract[180]	giv[175]|new[176]|new[178]|new[180]	_	_
22-22	3681-3691	especially	abstract[175]|abstract[176]|place[178]|abstract[180]|abstract[182]	giv[175]|new[176]|new[178]|new[180]|giv[182]	_	_
22-23	3692-3694	of	abstract[175]|abstract[176]|place[178]|abstract[180]|abstract[182]	giv[175]|new[176]|new[178]|new[180]|giv[182]	_	_
22-24	3695-3702	glucose	abstract[175]|abstract[176]|place[178]|abstract[180]|substance|abstract[182]	giv[175]|new[176]|new[178]|new[180]|new|giv[182]	_	_
22-25	3703-3713	metabolism	abstract[175]|abstract[176]|place[178]|abstract[180]|abstract[182]	giv[175]|new[176]|new[178]|new[180]|giv[182]	_	_
22-26	3714-3715	.	_	_	_	_

#Text=Within the canonical Wnt signaling pathway , β-catenin is the central player .
23-1	3716-3722	Within	_	_	_	_
23-2	3723-3726	the	place[185]	giv[185]	coref	24-9[189_185]
23-3	3727-3736	canonical	place[185]	giv[185]	_	_
23-4	3737-3740	Wnt	abstract|place[185]	giv|giv[185]	coref	28-9
23-5	3741-3750	signaling	abstract|place[185]	giv|giv[185]	coref	28-27
23-6	3751-3758	pathway	place[185]	giv[185]	_	_
23-7	3759-3760	,	_	_	_	_
23-8	3761-3770	β-catenin	abstract	new	coref	23-10[187_0]
23-9	3771-3773	is	_	_	_	_
23-10	3774-3777	the	abstract[187]	giv[187]	coref	24-3[188_187]
23-11	3778-3785	central	abstract[187]	giv[187]	_	_
23-12	3786-3792	player	abstract[187]	giv[187]	_	_
23-13	3793-3794	.	_	_	_	_

#Text=Normally , excess β-catenin is rapidly degraded by the ubiquitin-proteasome pathway .
24-1	3795-3803	Normally	_	_	_	_
24-2	3804-3805	,	_	_	_	_
24-3	3806-3812	excess	abstract[188]	giv[188]	coref	25-10[0_188]
24-4	3813-3822	β-catenin	abstract[188]	giv[188]	_	_
24-5	3823-3825	is	_	_	_	_
24-6	3826-3833	rapidly	_	_	_	_
24-7	3834-3842	degraded	_	_	_	_
24-8	3843-3845	by	_	_	_	_
24-9	3846-3849	the	place[189]	giv[189]	coref	25-3[191_189]
24-10	3850-3870	ubiquitin-proteasome	place[189]	giv[189]	_	_
24-11	3871-3878	pathway	place[189]	giv[189]	_	_
24-12	3879-3880	.	_	_	_	_

#Text=Activation of the pathway leads to the stabilization of β-catenin and its accumulation within the cytosol and the nucleus , where it interacts with T-cell factor/lymphoid enhancer-binding factor ( TCF/LEF ) transcription factors and thereby regulates transcription of multiple target genes .
25-1	3881-3891	Activation	abstract[190]	new[190]	_	_
25-2	3892-3894	of	abstract[190]	new[190]	_	_
25-3	3895-3898	the	abstract[190]|place[191]	new[190]|giv[191]	ana	25-12[0_191]
25-4	3899-3906	pathway	abstract[190]|place[191]	new[190]|giv[191]	_	_
25-5	3907-3912	leads	_	_	_	_
25-6	3913-3915	to	_	_	_	_
25-7	3916-3919	the	event[192]	new[192]	_	_
25-8	3920-3933	stabilization	event[192]	new[192]	_	_
25-9	3934-3936	of	event[192]	new[192]	_	_
25-10	3937-3946	β-catenin	event[192]|abstract	new[192]|giv	coref	30-9[240_0]
25-11	3947-3950	and	_	_	_	_
25-12	3951-3954	its	place|abstract[195]	giv|new[195]	ana|ana	25-22|25-22
25-13	3955-3967	accumulation	abstract[195]	new[195]	_	_
25-14	3968-3974	within	abstract[195]	new[195]	_	_
25-15	3975-3978	the	abstract[195]|place[196]	new[195]|new[196]	_	_
25-16	3979-3986	cytosol	abstract[195]|place[196]	new[195]|new[196]	_	_
25-17	3987-3990	and	abstract[195]	new[195]	_	_
25-18	3991-3994	the	abstract[195]|place[197]	new[195]|new[197]	_	_
25-19	3995-4002	nucleus	abstract[195]|place[197]	new[195]|new[197]	_	_
25-20	4003-4004	,	_	_	_	_
25-21	4005-4010	where	_	_	_	_
25-22	4011-4013	it	place	giv	coref	26-13[209_0]
25-23	4014-4023	interacts	_	_	_	_
25-24	4024-4028	with	_	_	_	_
25-25	4029-4035	T-cell	abstract[199]	giv[199]	appos	25-30[0_199]
25-26	4036-4051	factor/lymphoid	abstract[199]	giv[199]	_	_
25-27	4052-4068	enhancer-binding	abstract[199]	giv[199]	_	_
25-28	4069-4075	factor	abstract[199]	giv[199]	_	_
25-29	4076-4077	(	_	_	_	_
25-30	4078-4085	TCF/LEF	abstract	giv	_	_
25-31	4086-4087	)	_	_	_	_
25-32	4088-4101	transcription	abstract|abstract[202]	new|giv[202]	coref|coref	25-37[203_0]|25-37[203_0]
25-33	4102-4109	factors	abstract[202]	giv[202]	_	_
25-34	4110-4113	and	_	_	_	_
25-35	4114-4121	thereby	_	_	_	_
25-36	4122-4131	regulates	_	_	_	_
25-37	4132-4145	transcription	abstract[203]	giv[203]	coref	31-9[243_203]
25-38	4146-4148	of	abstract[203]	giv[203]	_	_
25-39	4149-4157	multiple	abstract[203]|abstract[204]	giv[203]|new[204]	coref	31-26[250_204]
25-40	4158-4164	target	abstract[203]|abstract[204]	giv[203]|new[204]	_	_
25-41	4165-4170	genes	abstract[203]|abstract[204]	giv[203]|new[204]	_	_
25-42	4171-4172	.	_	_	_	_

#Text=During recent years , a multitude of other crosstalks and co-operations affecting the pathway have been identified .
26-1	4173-4179	During	_	_	_	_
26-2	4180-4186	recent	time[205]	new[205]	_	_
26-3	4187-4192	years	time[205]	new[205]	_	_
26-4	4193-4194	,	_	_	_	_
26-5	4195-4196	a	abstract[206]	new[206]	_	_
26-6	4197-4206	multitude	abstract[206]	new[206]	_	_
26-7	4207-4209	of	abstract[206]	new[206]	_	_
26-8	4210-4215	other	abstract[206]|abstract[207]	new[206]|new[207]	_	_
26-9	4216-4226	crosstalks	abstract[206]|abstract[207]	new[206]|new[207]	_	_
26-10	4227-4230	and	abstract[206]	new[206]	_	_
26-11	4231-4244	co-operations	abstract[206]|abstract	new[206]|new	_	_
26-12	4245-4254	affecting	_	_	_	_
26-13	4255-4258	the	place[209]	giv[209]	_	_
26-14	4259-4266	pathway	place[209]	giv[209]	_	_
26-15	4267-4271	have	_	_	_	_
26-16	4272-4276	been	_	_	_	_
26-17	4277-4287	identified	_	_	_	_
26-18	4288-4289	.	_	_	_	_

#Text=Interestingly , variants of the TCF-4 ( TCF7L2 ) gene have been associated with increased risk of type 2 diabetes .
27-1	4290-4303	Interestingly	_	_	_	_
27-2	4304-4305	,	_	_	_	_
27-3	4306-4314	variants	abstract[210]	new[210]	_	_
27-4	4315-4317	of	abstract[210]	new[210]	_	_
27-5	4318-4321	the	abstract[210]|abstract[211]	new[210]|new[211]	appos	27-8[0_211]
27-6	4322-4327	TCF-4	abstract[210]|abstract[211]	new[210]|new[211]	_	_
27-7	4328-4329	(	abstract[210]	new[210]	_	_
27-8	4330-4336	TCF7L2	abstract[210]|abstract	new[210]|giv	_	_
27-9	4337-4338	)	abstract[210]	new[210]	_	_
27-10	4339-4343	gene	abstract[210]|abstract	new[210]|new	coref	31-19
27-11	4344-4348	have	_	_	_	_
27-12	4349-4353	been	_	_	_	_
27-13	4354-4364	associated	_	_	_	_
27-14	4365-4369	with	_	_	_	_
27-15	4370-4379	increased	abstract[214]	new[214]	_	_
27-16	4380-4384	risk	abstract[214]	new[214]	_	_
27-17	4385-4387	of	abstract[214]	new[214]	_	_
27-18	4388-4392	type	abstract[214]|abstract[215]	new[214]|new[215]	_	_
27-19	4393-4394	2	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
27-20	4395-4403	diabetes	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
27-21	4404-4405	.	_	_	_	_

#Text=Based on that knowledge , we hypothesized that Wnt ligands as secreted , cysteine-rich proteins are susceptible to α-DC-mediated modifications and that glycation might modulate their signaling activities .
28-1	4406-4411	Based	_	_	_	_
28-2	4412-4414	on	_	_	_	_
28-3	4415-4419	that	abstract[217]	new[217]	_	_
28-4	4420-4429	knowledge	abstract[217]	new[217]	_	_
28-5	4430-4431	,	_	_	_	_
28-6	4432-4434	we	person	acc	ana	29-5
28-7	4435-4447	hypothesized	_	_	_	_
28-8	4448-4452	that	_	_	_	_
28-9	4453-4456	Wnt	abstract|substance[220]	giv|new[220]	coref|coref	31-27|31-27
28-10	4457-4464	ligands	substance[220]	new[220]	_	_
28-11	4465-4467	as	_	_	_	_
28-12	4468-4476	secreted	_	_	_	_
28-13	4477-4478	,	_	_	_	_
28-14	4479-4492	cysteine-rich	substance[221]	giv[221]	ana	28-26[0_221]
28-15	4493-4501	proteins	substance[221]	giv[221]	_	_
28-16	4502-4505	are	_	_	_	_
28-17	4506-4517	susceptible	_	_	_	_
28-18	4518-4520	to	_	_	_	_
28-19	4521-4534	α-DC-mediated	abstract[222]	giv[222]	_	_
28-20	4535-4548	modifications	abstract[222]	giv[222]	_	_
28-21	4549-4552	and	_	_	_	_
28-22	4553-4557	that	_	_	_	_
28-23	4558-4567	glycation	substance	giv	_	_
28-24	4568-4573	might	_	_	_	_
28-25	4574-4582	modulate	_	_	_	_
28-26	4583-4588	their	substance|abstract[226]	giv|new[226]	_	_
28-27	4589-4598	signaling	abstract|abstract[226]	giv|new[226]	_	_
28-28	4599-4609	activities	abstract[226]	new[226]	_	_
28-29	4610-4611	.	_	_	_	_

#Text=For this study , we decided to use Wnt3a as a proof of principle to study effects of GO-treatment on Wnt3a conditioned medium ( Wnt3a CM ) .
29-1	4612-4615	For	_	_	_	_
29-2	4616-4620	this	abstract[227]	new[227]	_	_
29-3	4621-4626	study	abstract[227]	new[227]	_	_
29-4	4627-4628	,	_	_	_	_
29-5	4629-4631	we	person	giv	ana	30-1
29-6	4632-4639	decided	_	_	_	_
29-7	4640-4642	to	_	_	_	_
29-8	4643-4646	use	_	_	_	_
29-9	4647-4652	Wnt3a	organization	new	coref	29-21
29-10	4653-4655	as	_	_	_	_
29-11	4656-4657	a	_	_	_	_
29-12	4658-4663	proof	_	_	_	_
29-13	4664-4666	of	_	_	_	_
29-14	4667-4676	principle	abstract	new	_	_
29-15	4677-4679	to	_	_	_	_
29-16	4680-4685	study	_	_	_	_
29-17	4686-4693	effects	abstract[231]	giv[231]	_	_
29-18	4694-4696	of	abstract[231]	giv[231]	_	_
29-19	4697-4709	GO-treatment	abstract[231]|object	giv[231]|new	_	_
29-20	4710-4712	on	_	_	_	_
29-21	4713-4718	Wnt3a	abstract|object[234]	giv|new[234]	coref|appos|coref|appos	29-25|29-25[236_234]|29-25|29-25[236_234]
29-22	4719-4730	conditioned	object[234]	new[234]	_	_
29-23	4731-4737	medium	object[234]	new[234]	_	_
29-24	4738-4739	(	_	_	_	_
29-25	4740-4745	Wnt3a	abstract|object[236]	giv|giv[236]	_	_
29-26	4746-4748	CM	object[236]	giv[236]	_	_
29-27	4749-4750	)	_	_	_	_
29-28	4751-4752	.	_	_	_	_

#Text=We observed that the ratio of phospho-β-catenin to total β-catenin increased .
30-1	4753-4755	We	person	giv	_	_
30-2	4756-4764	observed	_	_	_	_
30-3	4765-4769	that	_	_	_	_
30-4	4770-4773	the	quantity[238]	new[238]	_	_
30-5	4774-4779	ratio	quantity[238]	new[238]	_	_
30-6	4780-4782	of	quantity[238]	new[238]	_	_
30-7	4783-4800	phospho-β-catenin	quantity[238]|substance	new[238]|new	_	_
30-8	4801-4803	to	_	_	_	_
30-9	4804-4809	total	abstract[240]	giv[240]	_	_
30-10	4810-4819	β-catenin	abstract[240]	giv[240]	_	_
30-11	4820-4829	increased	_	_	_	_
30-12	4830-4831	.	_	_	_	_

#Text=As a further consequence , Wnt3a-induced activation of the β-catenin/TCF transcription complex was reduced as shown by reporter gene assays and by decreased expression of endogenous Wnt target genes .
31-1	4832-4834	As	_	_	_	_
31-2	4835-4836	a	_	_	_	_
31-3	4837-4844	further	_	_	_	_
31-4	4845-4856	consequence	_	_	_	_
31-5	4857-4858	,	_	_	_	_
31-6	4859-4872	Wnt3a-induced	abstract[241]	new[241]	_	_
31-7	4873-4883	activation	abstract[241]	new[241]	_	_
31-8	4884-4886	of	abstract[241]	new[241]	_	_
31-9	4887-4890	the	abstract[241]|abstract[243]	new[241]|giv[243]	_	_
31-10	4891-4904	β-catenin/TCF	abstract[241]|abstract|abstract[243]	new[241]|new|giv[243]	_	_
31-11	4905-4918	transcription	abstract[241]|abstract[243]	new[241]|giv[243]	_	_
31-12	4919-4926	complex	abstract[241]|abstract[243]	new[241]|giv[243]	_	_
31-13	4927-4930	was	_	_	_	_
31-14	4931-4938	reduced	_	_	_	_
31-15	4939-4941	as	_	_	_	_
31-16	4942-4947	shown	_	_	_	_
31-17	4948-4950	by	_	_	_	_
31-18	4951-4959	reporter	person|abstract[246]	new|new[246]	_	_
31-19	4960-4964	gene	abstract|abstract[246]	giv|new[246]	_	_
31-20	4965-4971	assays	abstract[246]	new[246]	_	_
31-21	4972-4975	and	_	_	_	_
31-22	4976-4978	by	_	_	_	_
31-23	4979-4988	decreased	abstract[247]	new[247]	_	_
31-24	4989-4999	expression	abstract[247]	new[247]	_	_
31-25	5000-5002	of	abstract[247]	new[247]	_	_
31-26	5003-5013	endogenous	abstract[247]|abstract[250]	new[247]|giv[250]	_	_
31-27	5014-5017	Wnt	abstract[247]|abstract|abstract[250]	new[247]|giv|giv[250]	_	_
31-28	5018-5024	target	abstract[247]|abstract|abstract[250]	new[247]|new|giv[250]	_	_
31-29	5025-5030	genes	abstract[247]|abstract[250]	new[247]|giv[250]	_	_
31-30	5031-5032	.	_	_	_	_
